Imexpharm Corp
Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and mine… Read more
Imexpharm Corp (IMP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.070x
Based on the latest financial reports, Imexpharm Corp (IMP) has a cash flow conversion efficiency ratio of 0.070x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₫162.49 Billion) by net assets (₫2.31 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Imexpharm Corp - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Imexpharm Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Imexpharm Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Imexpharm Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Century Land Joint Stock Company
VN:CRE
|
-0.007x |
|
Balmer Lawrie & Company Limited
NSE:BALMLAWRIE
|
-0.035x |
|
Metemtur Yatırım Enerji Turizm ve İnşaat A.Ş.
IS:METUR
|
0.134x |
|
Regulus Resources Inc
OTCQX:RGLSF
|
-0.015x |
|
Fujian Jinsen Forestry Co Ltd
SHE:002679
|
-0.009x |
|
Karelia Tobacco Company Inc
AT:KARE
|
0.022x |
|
ESR-REIT
PINK:CGIUF
|
0.029x |
|
Hocheng Corp
TW:1810
|
0.029x |
Annual Cash Flow Conversion Efficiency for Imexpharm Corp (2019–2025)
The table below shows the annual cash flow conversion efficiency of Imexpharm Corp from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₫2.31 Trillion | ₫54.17 Billion | 0.023x | -76.29% |
| 2024-12-31 | ₫2.18 Trillion | ₫216.27 Billion | 0.099x | +610.25% |
| 2023-12-31 | ₫2.08 Trillion | ₫-40.47 Billion | -0.019x | -109.71% |
| 2022-12-31 | ₫1.89 Trillion | ₫378.60 Billion | 0.200x | +52.68% |
| 2021-12-31 | ₫1.79 Trillion | ₫234.88 Billion | 0.131x | +209.64% |
| 2020-12-31 | ₫1.73 Trillion | ₫73.15 Billion | 0.042x | -1.04% |
| 2019-12-31 | ₫1.56 Trillion | ₫66.59 Billion | 0.043x | -- |